Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK0529 in Hospitalized Infants With Respiratory Syncytial Virus Infection
NCT06775405Phase 3Completed
- Sponsor
- Ark Biosciences
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ziresovir in respiratory syncytial virus infection (RSV), sponsored by Ark Biosciences. Started Feb 2024; status: completed.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06775405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06775405.